Monitor for FDA advisory committee briefing documents and potential label discussions ahead of the Q1 2027 PDUFA date. The strong Phase 3 data de-risks approval, but the binary regulatory event remains the key catalyst. Watch for any safety signals or manufacturing issues in the review process. The EMA review adds a second major regulatory catalyst.
TAK drugs
TAK drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 14 $18.60entry
- T+1 · 2mo ago +0.54%α +1.00% · $18.70
- T+5 · 8w ago +1.56%α +1.45% · $18.89
- T+20 · 5w ago +0.43%α −1.83% · $18.68
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Takeda announced FDA Priority Review acceptance of its NDA for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, with a PDUFA target in Q1 2027. Phase 3 data showed strong efficacy across endpoints (e.g., ~70% sPGA 0/1 at week 16) with a clean safety profile, positioning it as a potential best-in-class oral TYK2 inhibitor. The EMA also accepted the MAA, and the filing has no impact on FY2027 guidance, making this a significant pipeline catalyst but with binary regulatory risk ahead.
Key Facts
- FDA accepted NDA under Priority Review for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis.
- PDUFA target action date is Q1 2027.
- Phase 3 LATITUDE PsO 3001/3002 studies met all co-primary and 44 ranked secondary endpoints (p<0.001).
- At week 16, 71% (3001) and 69% (3002) of zasocitinib patients achieved sPGA 0/1 vs 11%/13% placebo.
- PASI 75 at week 16: 76% (3001) and 71% (3002) vs 12% placebo.
- PASI 100 at week 16: 33% (3001) and 25% (3002) vs <1% placebo.
- EMA also accepted the MAA for zasocitinib in plaque psoriasis.
- No new safety signals; most common AEs were URTI (10.1%), nasopharyngitis (6.2%), and acne (6.5%).
- NDA filing has no significant impact on FY2027 consolidated financial forecast.
- Takeda is also evaluating zasocitinib in Phase 3 psoriatic arthritis and Phase 2 Crohn's, UC, vitiligo, and hidradenitis suppurativa.
Financial Impact
Pipeline catalyst with blockbuster potential; zasocitinib could address a large psoriasis market (66.4M patients globally). No immediate revenue impact as drug is not yet approved.
Risk Factors
- Regulatory risk: FDA could issue a Complete Response Letter (CRL) or require additional data.
- Commercial risk: Competition from existing oral (apremilast, deucravacitinib) and biologic therapies.
- Execution risk: Manufacturing scale-up and launch execution for a potential blockbuster.
- Pricing and reimbursement risk in a competitive psoriasis market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000337 |
| Document: 0001395064-26-000337-index-headers.html | 0001395064-26-000337 |
| Document: 0001395064-26-000337-index.html | 0001395064-26-000337 |
| Document: 0001395064-26-000337.txt | 0001395064-26-000337 |
Track record
18 reports on TAK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
- Oct 29, 202618d ago 6-K Neutral 4/10 No price data
- Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
- Sep 14, 20269w ago 6-K Bullish 7/10 Viewing Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
- Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers